Last updated on August 2019

A Study of LY3434172 a PD-1 and PD-L1 Bispecific Antibody in Advanced Cancer


Brief description of study

The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3434172, a PD-1/PD-L1 bispecific antibody, in participants with advanced solid tumors.

Clinical Study Identifier: NCT03936959

Find a site near you

Start Over